Prenatal Transplantation of Hematopoietic Stem Cells: Overview

  • D. V. Surbek
  • W. Holzgreve
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 33)


In the last 25 years, extensive progress has been made in the prenatal diagnosis of congenital diseases using non-invasive and invasive techniques. In contrast to prenatal diagnosis, prenatal therapy has shown limited success so far. Therefore, if a severe congenital disease is diagnosed early in gestation, many parents choose to terminate pregnancy. Prenatal transfer of hematopoietic stem cells (HSC) is a promising approach to successfully treat fetuses affected by hematologic, immunologic, or metabolic diseases. Recently, clinical success has been achieved (Flake et al. 1996). The success, however, is limited to diseases where severe immunodeficiency is present in the fetus. This article aims to provide an overview of the current experience in animals and humans and to identify strategies to overcome the current obstacles.


Hematopoietic Stem Cell Hematopoietic Stem Cell Transplantation Chronic Granulomatous Disease Graft Versus Host Disease Metachromatic Leukodystrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Almeida-Porada G, Flake AW, Glimp HA, Zanjani ED (1999) Cotransplantation of stroma results in enhancement and early expression of donor hematopoietic stem cells in utero. Exp Hematol 27: 1569–1575PubMedCrossRefGoogle Scholar
  2. Elwood ET, Larsen CP, Maurer DH et al (1998) Microchimerism and rejection in clinical transplantation. Lancet 349: 1358–1360CrossRefGoogle Scholar
  3. Flake AW, Zanjani ED (1999) In utero hematopoietic stem cell transplantation: ontogenetic opportunities and biologic barriers. Blood 94: 2179–2191PubMedGoogle Scholar
  4. Flake AW, Roncarolo MG, Puck JM et al (1996) Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med 335: 1806–1810PubMedCrossRefGoogle Scholar
  5. Surbek DV, Holzgreve W, Jansen W et al (1998) Quantitative immunophenotypic characterization, cryopreservation, and enrichment of second and third trimester human fetal cord blood hematopoietic stem/progenitor cells. Am J Obstet Gynecol 179: 1228–1233PubMedCrossRefGoogle Scholar
  6. Surbek DV, Gratwohl A, Holzgreve W (1999) In utero hematopoietic stem cell transfer: current status and future strategies. Eur J Obstet Gynecol Reprod Biol 85: 109–115PubMedCrossRefGoogle Scholar
  7. Thilaganathan B, Nicolaides KH (1993) Intrauterine bone-marrow transplantation at 12 weeks’ gestation. Lancet 342: 243CrossRefGoogle Scholar
  8. Zanjani ED, Anderson WF (1999) Prospects for in utero human gene therapy. Science 285: 2084–2088PubMedCrossRefGoogle Scholar
  9. Zanjani ED, Flake AW, Almeida-Porada G, Tran N, Papayannopoulou T (1999) Homing of human cells in fetal sheep model: modulation by anti-bodies activating or inhibiting very late activation antigen-4-dependent function. Blood 94: 2515–2522PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • D. V. Surbek
  • W. Holzgreve

There are no affiliations available

Personalised recommendations